|
Synonyms: PRO145223 | RG-7413 | RG7413 | rhuMAb Beta7
Compound class:
Antibody
Comment: Etrolizumab is a humanized monoclonal antibody targeting integrin receptors containing the ITGB7 (β7) subunit (namely α4β7 and αEβ7).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches indicate that US7528236 is the covering patent [4]. The likely candidate antibody clone is that designated hu504.32R. Etrolizumab has a slightly different mechanism of action compared to the already approved ulcerative colitis biologic vedolizumab (Entyvio®), which targets only α4β7 integrin. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Crohn's disease |
Disease Ontology:
DOID:8778 OMIM: 266600 Orphanet: ORPHA206 |
Phase 3 clinical candidate for CD. | |
| Ulcerative colitis |
Disease Ontology:
DOID:8577 OMIM: 266600 Orphanet: ORPHA771 |
Phase 3 clinical candidate for UC. | |
